Ronald Taylor - ResMed Lead Independent Director
| RMD Stock | USD 285.00 6.44 2.21% |
Director
Mr. Ronald R. Taylor is Lead Independent Director of the Company since July 1, 2013. He is chair of our nominating and governance committee and a member of our audit committee. In 1987, Mr. Taylor founded Pyxis Corporationrationration, a manufacturer of automated drug dispensers for hospitals, where he served as chairman, president, and chief executive officer until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served over 10 years in management roles at Allergan Pharmaceuticals. Mr. Taylor served as a director of Allergan plc, a NYSElisted specialty pharmaceutical company from 1994 until May 2018. During his tenure he served on the audit, compensation, and nominating and governance committees. From 1998 through 2014, he served as a director of Red Lion Hotels Corporation and was at various times a member of the nominating and governance, compensation and audit committees. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation. Mr. Taylor received a B.A. from the University of Saskatchewan and an M.A. from the University of California, Irvine since 2013.
| Age | 72 |
| Tenure | 12 years |
| Phone | 858-836-5000 |
| Web | https://www.resmed.co.in |
Ronald Taylor Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald Taylor against ResMed stock is an integral part of due diligence when investing in ResMed. Ronald Taylor insider activity provides valuable insight into whether ResMed is net buyers or sellers over its current business cycle. Note, ResMed insiders must abide by specific rules, including filing SEC forms every time they buy or sell ResMed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald Taylor over a year ago Acquisition by Ronald Taylor of 1768 shares of ResMed subject to Rule 16b-3 |
ResMed Management Efficiency
The company has Return on Asset of 0.1402 % which means that on every $100 spent on assets, it made $0.1402 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2586 %, implying that it generated $0.2586 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mark Buthman | West Pharmaceutical Services | 60 | |
| Myla LaiGoldman | West Pharmaceutical Services | 62 | |
| Gary Petersmeyer | The Cooper Companies, | 73 | |
| Patricia Morrison | Baxter International | 61 | |
| Thomas Stallkamp | Baxter International | 73 | |
| Timothy Ring | Becton Dickinson and | 63 | |
| Paolo Pucci | West Pharmaceutical Services | 59 | |
| Bertram Scott | Becton Dickinson and | 69 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| Christopher Jones | Becton Dickinson and | 65 | |
| Arthur MD | Alcon AG | 63 | |
| Jody Lindell | The Cooper Companies, | 69 | |
| David Melcher | Becton Dickinson and | 66 | |
| Nancy Schlichting | Baxter International | 66 | |
| Stephen Oesterle | Baxter International | 70 | |
| Catherine Burzik | Becton Dickinson and | 70 | |
| Michael Mahoney | Baxter International | 56 | |
| Claire Fraser | Becton Dickinson and | 65 | |
| William Feehery | West Pharmaceutical Services | 50 | |
| Thomas Hofmann | West Pharmaceutical Services | 68 | |
| James Gavin | Baxter International | 73 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.14 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
| AM BE, Chair Founder | ||
| Ronald Taylor, Lead Independent Director | ||
| Michael Rider, Chief Secretary | ||
| Vered Keisar, Chief Officer | ||
| Carlos MD, Chief Officer | ||
| Harjit Gill, Independent Director | ||
| Kaushik Ghoshal, Chief SaaS | ||
| Carol Burt, Independent Director | ||
| Peter Farrell, Non-Executive Chairman of the Board | ||
| Jim Hollingshead, President – sleep and respiratory care business | ||
| Michael Fliss, Chief Officer | ||
| Jan Witte, Independent Director | ||
| Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
| BE MBA, CEO Director | ||
| Karen Drexler, Independent Director | ||
| AM AM, Founder Chairman | ||
| Richard McHale, President – Respiratory Care Business | ||
| Constance Bienfait, Director Relations | ||
| Hemanth Reddy, Chief Officer | ||
| Urvashi Tyagi, Chief Technology Officer | ||
| Dawn Haake, Chief Officer | ||
| Justin Leong, President – Asia and Latin America | ||
| Robert Douglas, President, Chief Operating Officer | ||
| YvonneKatrin Pucknat, Chief Officer | ||
| Sallilyn Schwartz, Chief Officer | ||
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, CFO and Principal Accounting Officer | ||
| Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
| David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
| Richard Sulpizio, Independent Director | ||
| Michael Farrell, Chief Executive Officer, Director | ||
| Jim Ellis, Chief Officer | ||
| Alastair Robertson, Chief Officer | ||
| Todd Friedman, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 42.38 B | ||||
| Shares Outstanding | 146.63 M | ||||
| Shares Owned By Insiders | 0.77 % | ||||
| Shares Owned By Institutions | 65.13 % | ||||
| Number Of Shares Shorted | 9.38 M | ||||
| Price To Earning | 73.48 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.